PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis

NYSE:PBH • US74112D1019

66.52 USD
+0.55 (+0.83%)
Last: Feb 12, 2026, 02:11 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

PBH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. PBH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PBH has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year PBH was profitable.
  • PBH had a positive operating cash flow in the past year.
  • Of the past 5 years PBH 4 years were profitable.
  • Each year in the past 5 years PBH had a positive operating cash flow.
PBH Yearly Net Income VS EBIT VS OCF VS FCFPBH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

1.2 Ratios

  • PBH's Return On Assets of 5.83% is amongst the best of the industry. PBH outperforms 86.39% of its industry peers.
  • With an excellent Return On Equity value of 11.00%, PBH belongs to the best of the industry, outperforming 85.34% of the companies in the same industry.
  • The Return On Invested Capital of PBH (7.88%) is better than 85.86% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for PBH is below the industry average of 12.66%.
Industry RankSector Rank
ROA 5.83%
ROE 11%
ROIC 7.88%
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
PBH Yearly ROA, ROE, ROICPBH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 18.09%, PBH belongs to the top of the industry, outperforming 90.05% of the companies in the same industry.
  • In the last couple of years the Profit Margin of PBH has grown nicely.
  • PBH has a Operating Margin of 31.00%. This is amongst the best in the industry. PBH outperforms 94.24% of its industry peers.
  • In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
  • PBH has a better Gross Margin (56.10%) than 68.06% of its industry peers.
  • PBH's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 31%
PM (TTM) 18.09%
GM 56.1%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
PBH Yearly Profit, Operating, Gross MarginsPBH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PBH is destroying value.
  • The number of shares outstanding for PBH has been reduced compared to 1 year ago.
  • The number of shares outstanding for PBH has been reduced compared to 5 years ago.
  • Compared to 1 year ago, PBH has an improved debt to assets ratio.
PBH Yearly Shares OutstandingPBH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
PBH Yearly Total Debt VS Total AssetsPBH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • PBH has an Altman-Z score of 2.61. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • PBH has a better Altman-Z score (2.61) than 65.44% of its industry peers.
  • PBH has a debt to FCF ratio of 3.97. This is a good value and a sign of high solvency as PBH would need 3.97 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.97, PBH belongs to the top of the industry, outperforming 86.91% of the companies in the same industry.
  • PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
  • PBH has a Debt to Equity ratio of 0.55. This is in the lower half of the industry: PBH underperforms 64.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.97
Altman-Z 2.61
ROIC/WACC0.89
WACC8.87%
PBH Yearly LT Debt VS Equity VS FCFPBH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.3 Liquidity

  • PBH has a Current Ratio of 3.70. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
  • PBH has a Current ratio (3.70) which is in line with its industry peers.
  • A Quick Ratio of 2.51 indicates that PBH has no problem at all paying its short term obligations.
  • PBH has a Quick ratio (2.51) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 2.51
PBH Yearly Current Assets VS Current LiabilitesPBH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 6.92% over the past year.
  • The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
  • The Revenue has been growing slightly by 1.10% in the past year.
  • The Revenue has been growing slightly by 3.39% on average over the past years.
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%

3.2 Future

  • Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 4.28% on average per year.
  • PBH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.71% yearly.
EPS Next Y1.56%
EPS Next 2Y3.7%
EPS Next 3Y3.57%
EPS Next 5Y4.28%
Revenue Next Year-2.1%
Revenue Next 2Y0.04%
Revenue Next 3Y0.72%
Revenue Next 5Y0.71%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PBH Yearly Revenue VS EstimatesPBH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
PBH Yearly EPS VS EstimatesPBH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 14.85, which indicates a correct valuation of PBH.
  • 86.91% of the companies in the same industry are more expensive than PBH, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of PBH to the average of the S&P500 Index (28.18), we can say PBH is valued slightly cheaper.
  • PBH is valuated correctly with a Price/Forward Earnings ratio of 13.65.
  • 85.34% of the companies in the same industry are more expensive than PBH, based on the Price/Forward Earnings ratio.
  • PBH is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.01, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 14.85
Fwd PE 13.65
PBH Price Earnings VS Forward Price EarningsPBH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaply inside the industry as 88.48% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, PBH is valued cheaper than 89.01% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.32
EV/EBITDA 10.75
PBH Per share dataPBH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)9.53
PEG (5Y)1.67
EPS Next 2Y3.7%
EPS Next 3Y3.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PBH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRESTIGE CONSUMER HEALTHCARE

NYSE:PBH (2/12/2026, 2:11:13 PM)

66.52

+0.55 (+0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners108.83%
Inst Owner Change0.06%
Ins Owners1.31%
Ins Owner Change-0.38%
Market Cap3.15B
Revenue(TTM)1.14B
Net Income(TTM)200.84M
Analysts84
Price Target78.03 (17.3%)
Short Float %4.37%
Short Ratio5.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)-1.29%
PT rev (3m)-5.32%
EPS NQ rev (1m)0.63%
EPS NQ rev (3m)-7.48%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)0.88%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)-2.11%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)0.27%
Valuation
Industry RankSector Rank
PE 14.85
Fwd PE 13.65
P/S 2.83
P/FCF 12.32
P/OCF 11.95
P/B 1.72
P/tB N/A
EV/EBITDA 10.75
EPS(TTM)4.48
EY6.73%
EPS(NY)4.87
Fwd EY7.32%
FCF(TTM)5.4
FCFY8.12%
OCF(TTM)5.57
OCFY8.37%
SpS23.47
BVpS38.57
TBVpS-21.02
PEG (NY)9.53
PEG (5Y)1.67
Graham Number62.35
Profitability
Industry RankSector Rank
ROA 5.83%
ROE 11%
ROCE 10.41%
ROIC 7.88%
ROICexc 8.17%
ROICexgc 70.59%
OM 31%
PM (TTM) 18.09%
GM 56.1%
FCFM 23%
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.97
Debt/EBITDA 2.71
Cap/Depr 27.11%
Cap/Sales 0.72%
Interest Coverage 7.8
Cash Conversion 70.49%
Profit Quality 127.19%
Current Ratio 3.7
Quick Ratio 2.51
Altman-Z 2.61
F-Score7
WACC8.87%
ROIC/WACC0.89
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
EPS Next Y1.56%
EPS Next 2Y3.7%
EPS Next 3Y3.57%
EPS Next 5Y4.28%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%
Revenue Next Year-2.1%
Revenue Next 2Y0.04%
Revenue Next 3Y0.72%
Revenue Next 5Y0.71%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year6.22%
EBIT Next 3Y3.43%
EBIT Next 5Y2.82%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%

PRESTIGE CONSUMER HEALTHCARE / PBH FAQ

What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?

ChartMill assigns a fundamental rating of 6 / 10 to PBH.


Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?

ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.


What is the profitability of PBH stock?

PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.


What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?

The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.56% in the next year.